Literature DB >> 2158396

Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.

T Utsugi1, M R Mattern, C K Mirabelli, N Hanna.   

Abstract

A combination of tumor necrosis factor (TNF) and the topoisomerase I inhibitor, camptothecin, or the topoisomerase II inhibitors, teniposide and amsacrine, produced dose-dependent synergistic cytotoxicity against the murine L929 fibrosarcoma cells. Similar synergy was not observed with a combination of TNF and bleomycin. To define the role of TNF in the augmentation of tumor cell killing by topoisomerase I or II inhibitors, the effect of TNF on the production of enzyme-linked DNA strand breaks induced in cells by topoisomerase inhibitors was investigated. L929 cells incubated for 1 h with the topoisomerase inhibitors contained protein-linked strand breaks. In contrast, TNF alone did not induce DNA strand breakage. However, when cells were incubated simultaneously with TNF and camptothecin, amsacrine, Adriamycin, actinomycin D, teniposide, or etoposide, increased numbers of strand breaks were produced. Preincubation of the cells with TNF for 30 min or 3 h before the addition of camptothecin or etoposide resulted in no more strand breaks than that observed in cells incubated with the drugs alone. TNF treatment of L929 cells produced a rapid and transient increase in specific activity of extractable topoisomerases I and II. These increases were maximum at 2-5 min of TNF treatment and by 30 min the activities of extractable enzymes were equal to or less than those detected in extracts from untreated cell controls. The transient nature of the increase in extractable topoisomerase activity may explain the kinetics and significance of the order of addition of TNF and inhibitors for maximal synergistic activity. These data are consistent also with a role for topoisomerase-linked DNA lesions in the TNF-mediated potentiation of killing of L929 cells by topoisomerase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158396

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

2.  "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).

Authors:  G Cimoli; M Valenti; E Noviello; S Parodi; A Mazzoni; E Rovini; F De Sessa; P Russo
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 3.  Topoisomerase II in multiple drug resistance.

Authors:  G A Hofmann; M R Mattern
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Effects of tumor necrosis factor alpha, interferon alpha and interferon gamma on non-lymphoid leukemia cell lines: growth inhibition, differentiation induction and drug sensitivity modulation.

Authors:  A Kikuchi; V Holán; J Minowada
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.

Authors:  A L Ellis; B Nowak; W Plunkett; L A Zwelling
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.

Authors:  Y Aoyagi; T Kobunai; T Utsugi; K Wierzba; Y Yamada
Journal:  Jpn J Cancer Res       Date:  2000-05

7.  Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.

Authors:  T Utsugi; K Aoyagi; T Asao; S Okazaki; Y Aoyagi; M Sano; K Wierzba; Y Yamada
Journal:  Jpn J Cancer Res       Date:  1997-10

8.  Effects of tumour necrosis factor-alpha on BrdU incorporation in cultured human enterocytes.

Authors:  J McDevitt; C Feighery; C O'Farrelly; G Martin; D G Weir; D Kelleher
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

9.  Circumvention of atypical multidrug resistance with tumor necrosis factor.

Authors:  G Cimoli; M Valenti; S Parodi; F De Sessa; P Russo
Journal:  Jpn J Cancer Res       Date:  1994-02

10.  Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.

Authors:  G Orengo; E Noviello; G Cimoli; G Pagnan; S Parodi; M Venturini; P Conte; F Schenone; G Conzi; P Russo
Journal:  Jpn J Cancer Res       Date:  1992-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.